Range Financial Group LLC Has $2.08 Million Stock Position in Novo Nordisk A/S $NVO

Range Financial Group LLC increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 226.4% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 37,511 shares of the company’s stock after purchasing an additional 26,020 shares during the period. Range Financial Group LLC’s holdings in Novo Nordisk A/S were worth $2,081,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC boosted its stake in shares of Novo Nordisk A/S by 0.3% during the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after acquiring an additional 63,341 shares during the period. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after acquiring an additional 187,789 shares during the period. Kingstone Capital Partners Texas LLC lifted its holdings in Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the last quarter. Sustainable Growth Advisers LP boosted its position in Novo Nordisk A/S by 11.7% during the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after purchasing an additional 649,390 shares during the period. Finally, State Street Corp boosted its position in Novo Nordisk A/S by 0.8% during the second quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after purchasing an additional 47,430 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Stores Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approved Novo’s oral Wegovy pill, broadening how patients can take its leading GLP‑1 weight‑loss therapy and opening a large new addressable market for oral treatment forms. Novo Nordisk’s Wegovy Pill Wins U.S. Approval
• Positive Sentiment: Early analyst/coverage pieces highlight strong efficacy data for the oral Wegovy (noted mean weight loss and high share of patients >20% weight loss), positioning the pill as a potential market‑share and growth driver versus rivals. Novo Nordisk: Oral Weight-Loss To The Rescue
• Positive Sentiment: Market reaction: some outlets report a strong short‑term rally (double‑digit intraday moves in recent sessions) after the pill approval, reflecting renewed investor optimism about sales upside. Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK
• Positive Sentiment: Coverage suggests the FDA nod could lift healthcare ETFs and related peers as the oral GLP‑1 opportunity reshapes the sector, a tailwind for investor flows into NVO and peers. The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
• Positive Sentiment: Reports say Novo is pricing the oral Wegovy to undercut Eli Lilly in direct‑to‑consumer channels — a deliberate share‑capture strategy that should speed adoption even if it compresses unit economics. With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
• Neutral Sentiment: Interest/attention indicators: NVO is a trending stock on investor screens — increased search and mention volume can amplify short‑term volatility but isn’t a fundamental read. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Competitive landscape: coverage notes heightened rivalry with Eli Lilly (new oral entrants and filings). Competition increases execution risk but also validates a large market. The Weight Loss Drug Competition Is Heating Up
• Negative Sentiment: Pricing pressure in China: Novo has cut Wegovy prices in some Chinese provinces — reports say prices were nearly halved in places as the company preempts generic competition; this raises near‑term revenue and margin risk in a large market. Novo cuts Wegovy prices in some Chinese provinces, local media reports Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 22nd. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Finally, Jefferies Financial Group initiated coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Stock Down 1.9%

Shares of NYSE NVO opened at $51.40 on Tuesday. The company has a 50 day simple moving average of $49.27 and a 200 day simple moving average of $56.41. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The firm has a market cap of $229.51 billion, a PE ratio of 14.94 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.